Clinical Rheumatology

, Volume 30, Issue 5, pp 607–614 | Cite as

A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide

  • Amira A. Shahin
  • Soha M. El Desouky
  • Hania S. Zayed
Original Article


The aim of this work is to describe the outcome of a series of patients with hepatitis C virus (HCV)-related vasculitis who were treated with corticosteroids and I.V. cyclophosphamide without receiving any antiviral therapy. The data of 16 patients with HCV infection and vasculitis were retrospectively analyzed for the treatment outcome in the present study. Eleven patients were females (68.8%) with a mean age of 49.6 ± 10.0 years. Nine patients (56.2%) had medium-sized vessel vasculitis (group A) and seven patients (43.8%) had small vessel vasculitis (group B). Disease activity was assessed using the Birmingham Vasculitis Activity Score (BVAS 2003) and organ damage was assessed by the Vasculitis Damage Index (VDI). HCV infection was confirmed in all patients by the detection of antibodies to HCV in serum by ELISA and HCV RNA using qualitative PCR. Quantitative PCR was done using the branched DNA technique. None of our study patients had received antiviral therapy, but they all received I.V.-pulsed cyclophosphamide monthly for 6 months, then every 3 months for six times if needed, preceded by I.V. methylprednisolone. Twelve patients (75%) had undetectable viral load by the quantitative technique. The drop in mean BVAS recorded at different intervals was highly significant. Although there was a drop in the VDI mean between the first and second reading, it was not statistically significant. All patients responded to treatment. Seven patients (43.8%) had relapse. Two patients died (12.5%). One patient died from renal failure (group B) and another died from sepsis (group A). The treatment outcomes were not statistically significant between the two vasculitis groups. A subset of patients with HCV-related vasculitis and with low levels of viremia can be safely treated with corticosteroids and cyclophosphamide alone. Despite successful treatment, a significant proportion of patients relapse and some develop severe complications and death.


Corticosteroids Cyclophosphamide HCV vasculitis Medium size vessel vasculitis Small size vessel vasculitis 





  1. 1.
    Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, El Gohary LA, Ramy AH, Madwar MA, Rasenack J, Afdal NH (2006) Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 43(5):923–931. Erratum in: Hepatology 44(4):1055PubMedCrossRefGoogle Scholar
  2. 2.
    Sharaf Eldin N, Ismail S, Mansour H, Rekacewicz C, El-Houssinie M, El kafrawy S, El Aidi S,Abdel-Hamid M, Esmat G, Pol S, Fontanet A, Mohamed MK (2008) Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon 3(12)
  3. 3.
    Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology (Suppl):S21–S29Google Scholar
  4. 4.
    Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345:41–53PubMedCrossRefGoogle Scholar
  5. 5.
    Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC (2005) PEGylated interferon alpha-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52:911–5PubMedCrossRefGoogle Scholar
  6. 6.
    Cacoub P, Saadoun D, Sene D, Limal N, Piette JC (2005) Treatment of hepatitis C virus related systemic vasculitis. J Rheumatol 32:11Google Scholar
  7. 7.
    Manns MP, McHutchison JP, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958–65PubMedCrossRefGoogle Scholar
  8. 8.
    Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P et al (2002) Interferon alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46:3317–26PubMedCrossRefGoogle Scholar
  9. 9.
    Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E et al (2000) Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α. J Rheumatol 27:2172–8PubMedGoogle Scholar
  10. 10.
    Alric L, Plaisier E, Thebault S et al (2004) Influence of antiviral therapy in hepatitis C virus associated MPGN. Am J Kidney Dis 43:617–23PubMedCrossRefGoogle Scholar
  11. 11.
    Casato M, Agnello V, Pucillo LP et al (1997) Predictors of long-term response to high dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus. Blood 90:3865–73PubMedGoogle Scholar
  12. 12.
    Martins Junior EV, Gaburri AK, Chebli JM (2004) Cutaneous vasculitis with undetectable cryoglobulinemia in chronic hepatitis C. J Gastroenterol Hepatol 19:1220–1PubMedCrossRefGoogle Scholar
  13. 13.
    Levine JW, Gota C, Fessler B, Cooper SM, Calabrese L (2004) Persistent cryoglobulinemic vasculitis following successful HCV eradication (abstract). Arthritis Rheum 50:S125Google Scholar
  14. 14.
    Kimyai-Asadi A, Gohar K, Kang P, Usman A, Zeneberg R, Jih MH (2002) Mixed cryoglobulinemia secondary to interferon therapy for hepatitis C: case report and review of the literature. J Drugs Dermatol 1:72–5PubMedGoogle Scholar
  15. 15.
    Cacoub P, Maisonobe T, Gatel A, Servan J, Musset L, Piette JC (2001) Systemic vasculitis in patients with hepatitis C. J Rheumatol 28:109–18PubMedGoogle Scholar
  16. 16.
    Rutkove SB (1997) An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a. Arch Neurol 54:907–8PubMedGoogle Scholar
  17. 17.
    Cid MC, Hermandez-Rodriguez J, Robert J et al (1999) Interferon-alpha may exacerbate cryoglobulinemia-related ischemic manifestations: an adverse effect potentially related to its antiangiogenic activity. Arthritis Rheum 4(2):1051–5CrossRefGoogle Scholar
  18. 18.
    Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D (2008) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where we stand? Ann Rheum Dis 67:283–287PubMedCrossRefGoogle Scholar
  19. 19.
    Naarendorp M, Kallemuchikkal U, Nuovo GJ, Gorevic PD (2001) Longterm efficacy of interferon-α for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 28:2466–73PubMedGoogle Scholar
  20. 20.
    Landau DA, Saadoun D, Halfon P, Martinot-Peignoux M, Marcellin P, Fois E, Cacoub P (2008) Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 58:604–611PubMedCrossRefGoogle Scholar
  21. 21.
    Misiani R, Bellavita P, Fenili D et al (1994) Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751–6PubMedCrossRefGoogle Scholar
  22. 22.
    Ferri C, Marzo E, Longombardo G et al (1993) Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81:1132–6PubMedGoogle Scholar
  23. 23.
    Dammaco F, Sansonno D, Han JH et al (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84:3336–43Google Scholar
  24. 24.
    Ad hoc subcommittee of the American Academy of Neurology AIDS Task force (1991) Research criteria for diagnosis of chronic inflammatory demyelinating neuropathy. Neurology 41:617–618Google Scholar
  25. 25.
    Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N et al (2007) Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 66:283–292PubMedGoogle Scholar
  26. 26.
    Luqumani RA, Exley AR, Kitas GD, Bacon PA (1997) Disease assessment and management of the vasculitides. Ballieres Clin Rheumatol 11:423–446CrossRefGoogle Scholar
  27. 27.
    Exley A, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the VDI. Arthritis Rheum 40:371–380PubMedCrossRefGoogle Scholar
  28. 28.
    Exley A, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R (1998) Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 37:57–63PubMedCrossRefGoogle Scholar
  29. 29.
    Vassilopoulos D, Calabrese LH (2002) Hepatitis C virus infection and vasculitis. Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 46:585–97PubMedCrossRefGoogle Scholar
  30. 30.
    Ramos-Casals M, Trejo O, Garcia-Carrasco M, Font J (2003) Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. J Rheumatol 42:818–828CrossRefGoogle Scholar
  31. 31.
    Lamprecht P, Gause A, Gross WL (2000) Cryoglobulinemic vasculitis resistant to intermittent intravenous pulse cyclophosphamide therapy. Scand J Rheumatol 29:201–2PubMedCrossRefGoogle Scholar
  32. 32.
    Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P (2006) Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow up study. Arthritis Rheum 54:3696–706PubMedCrossRefGoogle Scholar
  33. 33.
    Conca P, Tarantino G (2009) Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy. World J Gastroentrol 15(19):2305–2308CrossRefGoogle Scholar
  34. 34.
    Marrinho RT, Pinto RM, Santos ML, de Moura MC (2004) Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativation (seroreversion) of anti-hepatitis C virus. Liver Int 24:413–418CrossRefGoogle Scholar
  35. 35.
    Carreno V, Bartolome J, Castillo I, Quiroga JA (2008) Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 18:139–157PubMedCrossRefGoogle Scholar
  36. 36.
    Pham TN, Michalak TI (2008) Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 14:2789–2793PubMedCrossRefGoogle Scholar
  37. 37.
    Caudai C, Padula MG, Bastianoni I, Valensin PE, Shyamala V, Han J, Boggianno CA, Almi P (1998) Antibody testing and RT-PCR results in hepatitis C virus (HCV) infection: HCV-RNA detection in PBMC of plasma viremia-negative HCV-seropositive persons. Infection 26(3):151–154PubMedCrossRefGoogle Scholar
  38. 38.
    Monia F, Lamia B, Jalel B, Samira M, Amel S, Azza F (2005) Cryoglobulinemia in chronic hepatits C virus infection. About 76 cases. Tunis Méd 83(11):664–8PubMedGoogle Scholar
  39. 39.
    Wong VS, Egner W, Elsey T, Brown D, Alexander GJ (1996) Incidence, character and clinical relevance of mixed cryoglobulinemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 104:25–31PubMedCrossRefGoogle Scholar
  40. 40.
    Narváez J, Biosca M, Perez-Vega C, Vilaseca-Momplet J (2003) Fulminant systemic vasculitis in a patient untreated asymptomatic chronic hepatitis C infection. Scand J Rheumatol 32:377–378Google Scholar
  41. 41.
    Sansonno D, Lauletta G, Nisi L, Gatti P, Pesola F, Pansini N, Dammaco F (2003) Nonenveloped HC core protein as constitutive antigen of cold precipitate immune complexes in type II mixed cryoglobulinaemia. Clin Exp Immunol 133:275–282PubMedCrossRefGoogle Scholar
  42. 42.
    Sansonno D, Dammaco F (2005) Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 5:227–236PubMedCrossRefGoogle Scholar
  43. 43.
    Lamprecht P, Moosig F, Gause A, Herlyn K, Csernok E, Hansen H, Gross WL (2001) Immunological and clinical follow-up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 60:385–390PubMedCrossRefGoogle Scholar
  44. 44.
    Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM (2005) Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32:1164–7PubMedGoogle Scholar
  45. 45.
    Thiele DL, Ducharme L, Cunningham MR et al (1996) Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Am J Gastroenterol 91:273–279Google Scholar

Copyright information

© Clinical Rheumatology 2010

Authors and Affiliations

  • Amira A. Shahin
    • 1
    • 2
  • Soha M. El Desouky
    • 1
  • Hania S. Zayed
    • 1
  1. 1.Department of Rheumatology and Rehabilitation, College of MedicineCairo UniversityCairoEgypt
  2. 2.GizaEgypt

Personalised recommendations